Articles from Atom Therapeutics

Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today Phase 2b/3 trial results showing lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia in Chinese patients will be presented at the American College of Rheumatology’s ACR Convergence 2026, November 6 – 11, in Orlando, FL. The data also confirm lingdolinurad achieved its primary and secondary endpoints in lowering serum uric acid (sUA) and dissolving tophi, an indicator of advanced chronic gout.

Atom Therapeutics, an innovative biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced the initiation of its Phase 3 clinical trial in China for lingdolinurad (ABP-671). The first patient has been successfully enrolled and dosed.

Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases including chronic and acute gout, announced today management will be available for one-on-one meetings with prospective partners for ABP-671 and ABP-745 in territories outside of China at the upcoming BIO-Europe Global Partnering 2025 meeting in Vienna.

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today it has enrolled the first patient in a multi-country Phase 2 trial of ABP-745, a novel anti-inflammatory drug, for treatment of painful acute gout flares.